Description

Dolcanatide (CAS No. 1092457-65-2) is an orally active peptide-based agonist of guanylate cyclase-C (GC-C), a key receptor in intestinal epithelial regulation. It exhibits a combination of laxative effects, anti-inflammatory activity, and anti-nociceptive properties. Research demonstrates its ability to support tight junction integrity and improve mucosal barrier function in preclinical gastrointestinal disease models. Manufactured at high purity (99.39%) under GMP conditions, Dolcanatide provides consistent and reliable performance for in-vitro and in-vivo experimental studies. Strictly for laboratory research use only.

Product Specifications

Mechanism of Action & Research Applications

Mechanism of Action:
Dolcanatide functions as an agonist of intestinal guanylate cyclase-C (GC-C), enhancing intracellular cyclic GMP levels. This action regulates fluid secretion, supports intestinal mucosal barrier integrity, and modulates sensory signaling in the gut.

Research Applications:

• Gastrointestinal Barrier Function: Supports tight junction maintenance and epithelial integrity in inflammatory conditions.

• Inflammatory Bowel Disease (IBD) Models: Reduces inflammation and promotes mucosal healing in preclinical colitis models.

• Visceral Pain & Sensitivity: Exhibits anti-nociceptive effects in models of visceral hypersensitivity.

• Gut Motility Studies: Demonstrates consistent laxative activity, aiding research in constipation-related disorders.

  

Side Effects (For Research Reference Only)

Dolcanatide is designed exclusively for in vitro or animal model research. No clinical safety data is available. Common observations in preclinical models may include amplified intestinal fluid secretion. Please follow standard laboratory safety protocols.

Disclaimer

Dolcanatide is strictly for laboratory research use only. It is not approved for clinical, diagnostic, or therapeutic use. Handle in accordance with your institution’s safety guidelines.